High HMGN1 levels drive leukemia in Down syndrome
Nature Genetics
April 21, 2014
A genetic cause of the link between Down syndrome and B cell acute lymphoblastic leukemia (B-ALL) in both mice and human cells is reported in a paper published online this week in Nature Genetics. The study identifies a promising drug target to treat B-ALL in Down syndrome.
People with Down syndrome are at a 20-fold risk of developing a type of B-ALL, an aggressive cancer of the white blood cells. David Weinstock and colleagues found that having three copies of a small region of 31 genes on chromosome 21 was sufficient to drive the cancer. Using a combination of experiments in mice and human cells, they found that increased levels of a specific protein, HMGN1, turns on the group of genes needed for the cancer to spread. The increase in HMGN1 levels was specific to Down syndrome B-ALL, but not other types of ALL.
The authors speculate that drugs that inhibit HMGN1 could prove useful for treating B-ALL in Down syndrome patients.
doi:10.1038/ng.2949
Research highlights
-
Jan 24
Engineering: 3D-printed vocal tract reproduces sound of ancient mummyScientific Reports
-
Jan 23
Stem cells: How stress turns mice greyNature
-
Jan 23
Immunology: Bringing HIV out of hidingNature
-
Jan 22
Earth science: Earth’s oldest known impact structure revealedNature Communications
-
Jan 22
Environment: Plant uptake of lead from solar cells assessedNature Communications
-
Jan 21
Environment: Barriers preventing prescribed burns for California wildfire management identifiedNature Sustainability
